Trial · NCT01076153
Recovery Time in Thai Patients With Upper or Lower Respiratory Tract Infections Treated With Klacid MR
NCT01076153, Completed, Abbott; results first posted 2011-06-29
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Recovery Time in Thai Patients With Upper or Lower Respiratory Tract Infections Treated With Klacid MR. Trials, record NCT01076153. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01076153
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Recovery Time in Thai Patients With Upper or Lower Respiratory Tract Infections Treated With Klacid MR
- NCT number
- NCT01076153
- Status
- Completed
- Enrollment
- 760 participants, actual
- Lead sponsor
- Abbott
- Conditions
- Respiratory Tract Infection
- Interventions
- Clarithromycin (Klacid® MR)
- First posted
- 2010-02-26
- Last updated
- 2011-07-12
- Results first posted
- 2011-06-29
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Average Time From Baseline to Recovery From Cough and Other Symptoms | Baseline to 14 days | Study participants were seen at an initial visit (baseline) and received Klacid treatment for 5 to 14 days. A medical appointment (visit or phone call) was made 6 to 14 days after the first visit. Participants' symptoms were rated using one of the following categories: resolved, improved, not changed, or worse. Associated dates were also recorded. Symptoms included, but were not limited to, cough, fever, and sore throat. Recovery was defined as the disappearance of all signs and symptoms of infection. |
| Secondary | Number and Type of Adverse Events | Baseline to 14 days | Adverse events were collected during the course of the study up to 30 days or 5 half-lives following the last dose of Klacid. The number of participants experiencing a serious or non-serious adverse event is summarized. See the Reported Adverse Event section for details. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Average Time From Baseline to Recovery From Cough and Other Symptoms | Baseline to 14 days | The per-protocol population consisted of 694 participants as 66 participants were excluded for protocol deviations (some more than 1): Age less than 18 years (22), took excluded drugs (17), took Klacid more than 14 days (16), took Klacid less than 5 days (11), added 250 mg Klacid to Klacid MR (5), and used injectable drugs (3). | Days | MEAN |
| SECONDARY | Number and Type of Adverse Events | Baseline to 14 days | The safety population included all participants who took at least 1 dose of Klacid. | Events | NUMBER |
Source ClinicalTrials.gov
Results by group6
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Average Time From Baseline to Recovery From Cough and Other Symptoms | Klacid MR (Total Number Recovered) | 7.06 | Standard Deviation 2.65 | Days | |
| Average Time From Baseline to Recovery From Cough and Other Symptoms | Klacid MR (URTI, Recovered) | 6.76 | Standard Deviation 2.11 | Days | |
| Average Time From Baseline to Recovery From Cough and Other Symptoms | Klacid MR (LRTI, Recovered) | 7.82 | Standard Deviation 3.75 | Days | |
| Average Time From Baseline to Recovery From Cough and Other Symptoms | Klacid MR (URTI and LRTI, Recovered) | 9.05 | Standard Deviation 3.08 | Days | |
| Number and Type of Adverse Events | Klacid MR | Serious Adverse Events | 0 | Events | |
| Number and Type of Adverse Events | Klacid MR | Non-serious Adverse Events | 7 | Events |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Klacid MR | 760 | |
| Overall Study | COMPLETED | Klacid MR | 749 | |
| Overall Study | NOT COMPLETED | Klacid MR | 11 |
Source ClinicalTrials.gov
Adverse events4
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Dysgeusia | Gastrointestinal disorders | Klacid MR | 3 | 760 | 4 |
| other | Abdominal pain | Gastrointestinal disorders | Klacid MR | 1 | 760 | 1 |
| other | Palpitations | Cardiac disorders | Klacid MR | 1 | 760 | 1 |
| other | Muscle strain | Musculoskeletal and connective tissue disorders | Klacid MR | 1 | 760 | 1 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Klacid MR | ||
| Total, other adverse events | Klacid MR | 5 | 760 |
| Total, serious adverse events | Klacid MR | 0 | 760 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01076153
GET https://conductscience.org/api/trials/v1/NCT01076153/registered